By killing cancer cells directly within the tumor, the treatment exposes the patient's unique, mutated cancer antigens to their immune system. This effectively trains immune cells to recognize and attack similar cancer cells throughout the body, creating a highly personalized, in-situ vaccine.
The company's drug formulation doesn't rely on specific cell receptors, which cancers often mutate to evade treatment. Instead, it uses a physical diffusion process to permeate any cancer cell, rendering receptor-based mutations irrelevant and overcoming a major hurdle in cancer therapy.
The company's technology is a delivery system. By containing potent compounds within the tumor via direct injection, it can make previously shelved drugs—those too toxic for systemic use—viable therapies, creating a new pipeline of cancer treatments.
Current chemotherapy doses are calculated using patient height and weight, a method from the 1800s. This metric has zero correlation with tumor size or burden, leading to suboptimal treatment efficacy for many cancer patients.